{
    "id": "dbpedia_6819_0",
    "rank": 83,
    "data": {
        "url": "https://www.cincinnatichildrens.org/research/divisions/c/cbdi/publications",
        "read_more_link": "",
        "language": "en",
        "title": "Cancer and Blood Diseases Institute",
        "top_image": "https://www.cincinnatichildrens.org/-/media/Cincinnati%20Childrens/Global%20Shared/icons/favicon-32x32.png",
        "meta_img": "https://www.cincinnatichildrens.org/-/media/Cincinnati%20Childrens/Global%20Shared/icons/favicon-32x32.png",
        "images": [
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/childrens-logo-new.png?iar=0&mh=500&mw=800",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/childrens-logo-new.png?iar=0&mh=500&mw=800",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/Navigation/Footer-Nav/blogiconimage2x.png?iar=0&mh=58&mw=58&hash=16C5C404AC405661A7D3982B5E0BA7FD",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/Navigation/Footer-Nav/blogiconimage2x.png?iar=0&mh=58&mw=58&hash=16C5C404AC405661A7D3982B5E0BA7FD",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/Navigation/Footer-Nav/us-news-60x70.png?iar=0&mh=70&mw=60&hash=306BCAB8FD889AE04B20682C92C306C4",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/Navigation/Footer-Nav/bptw.png?iar=0&mh=70&mw=60&hash=27CD5E8B5A8C470D9DE147D910C73FD3",
            "https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Global-Shared/Navigation/Footer-Nav/forbes-large-employer-footer.png?iar=0&mh=70&mw=60&hash=5A299800653A4C306E1E0172B740B3F7"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "BG; Davis",
            "JC; Fox",
            "LH; Vicente-Muñoz",
            "S; Lester",
            "C; Wells",
            "SI; Waltz",
            "C; Barreyro",
            "L; Sampson",
            "A; Hueneman",
            "K; Choi"
        ],
        "publish_date": null,
        "summary": "",
        "meta_description": "Our staff is active in their fields and regularly publish their research findings for their peers. View the publications from our researchers.",
        "meta_lang": "en",
        "meta_favicon": "/-/media/Cincinnati%20Childrens/Global%20Shared/icons/apple-touch-icon.png",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Abu-Shihab, Y; Nicolet, D; Mrózek, K; Routbort, M; Patel, KP; Walker, CJ; Buss, J; Stiff, A; Laganson, A; DiNardo, CD; Blachly, JS; Miles, LA; Eisfeld, A; Loghavi, S. BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML. Blood. 2023; 142:1575.\n\nAdair, JE; Androski, L; Bayigga, L; Bazira, D; Brandon, E; Dee, L; Deeks, S; Draz, M; Dubé, K; Dybul, M; Nsubuga, MS; Tisdale, JF; Verhoeyen, E; Dropulic, B. Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI). Gene Therapy (Basingstoke). 2023; 30:216-221.\n\nAlharbi, H; Daniel, EJ P; Thies, J; Chang, I; Goldner, DL; Ng, BG; Witters, P; Aqul, A; Velez-Bartolomei, F; Enns, GM; Freeze, HH; Lam, C; Edmondson, AC; He, M. Fractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic association. Journal of Inherited Metabolic Disease. 2023; 46:300-312.\n\nAmbrose, EE; Latham, TS; Songoro, P; Charles, M; Lane, AC; Stuber, SE; Makubi, AN; Ware, RE; Smart, LR. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. The Lancet Haematology. 2023; 10:e261-e271.\n\nAnand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Transplant Infectious Disease. 2023; 25:e14179.\n\nArnold, DE; Kaviany, S; Aluri, J; Murguia-Favela, L; Wright, NA; Loughran, TP; Powell, J; De Ravin, SS; Rao, VK; Holland, S; Bleesing, J; Bednarski, JJ; Connelly, JA; Cooper, M. Clinical Characteristics, Management, and Allogeneic Hematopoietic Cell Transplantation of Patients with Toll-like Receptor 8 Gain-of-Function Mutations. Blood. 2023; 142:936.\n\nAuletta, JJ; Holter-Chakrabarty, J; Jain, T; Miller, B; Ward, E; Khera, N; Gomez-Arteaga, A; Hall, A; Nemecek, E; Robb, D; Yusuf, RA; Davies, SM. Proceedings of the 2023 Second Annual ASTCT-NMDP ACCESS Initiative Workshop. Transplantation and cellular therapy. 2023; 29:739-746.\n\nAuletta, JJ; Khera, N; DeMartino, P; Kelkar, AH; Yusuf, RA; Davies, SM; Knutson, J; Beaver, E; Maloney, A; Majhail, NS. Assessing Medicaid Coverage for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy: A Project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative. Transplantation and cellular therapy. 2023; 29:713-720.\n\nAzhar, M; Kincaid, Z; Kesarwani, M; Menke, J; Schwieterman, J; Ansari, S; Reaves, A; Ahmed, A; Shehzad, R; Khan, A; Wunderlich, M; Latif, T; Seibel, W; Azam, M. Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Blood Advances. 2023; 7:1460-1476.\n\nAzucenas, CR; Stewart, M; Voulgaridou, A; Seu, K; Kalfa, TA. Inducible Knockout of Codanin-1: An Adult Mouse Model of Congenital Dyserythropoietic Anemia Type-I. Blood. 2023; 142:2450.\n\nBabic, I; Bryan, N; Cunningham, C; Sampson, A; Starczynowski, D; Nurmemmedov, E. Abstract 2759: Real-time cellular target engagement and protein quantification for drug discovery. Cancer Research. 2023; 83:2759.\n\nBahakel, H; Spieker, AJ; Stahl, A; Rahman, H; Amarin, J; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Englund, JA; Munoz, FM; Danziger-Isakov, L; Halasa, N. Immunogenicity and Safety of Alternative Influenza Vaccination Strategies in Repeated Seasons in Pediatric Hematopoietic-Cell Transplant Recipients. Journal of the Pediatric Infectious Diseases Society. 2023; 12:s21.\n\nBareja, R; Ismail, M; Martin, D; Nayate, A; Yadav, I; Labbad, M; Tamrazi, B; Salloum, R; Margol, A; Judkins, A; Iyer, S; de Blank, P; Tiwari, P. MDB-44. A TRANSFER LEARNING APPROACH FOR AUTOMATIC SEGMENTATION OF TUMOR SUB-COMPARTMENTS AND TUMOR HABITAT IN PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 2023; 25:i71-i72.\n\nBareja, R; Ismail, M; Martin, D; Nayate, A; Yadav, I; Labbad, M; Tamrazi, B; Salloum, R; Margol, A; Judkins, A; Iyer, S; de Blank, P; Tiwari, P. MDB-43. GRADIENT ENTROPY-BASED RADIOMIC RISK-SCORE FROM T1-WEIGHTED PRE-TREATMENT MRI SCANS CAN PREDICT SURVIVAL IN PEDIATRIC MEDULLOBLASTOMA. Neuro-Oncology. 2023; 25:i71.\n\nBarron, T; Yalçin, B; Mochizuki, A; Cantor, E; Shamardani, K; Tlais, D; Franson, A; Lyons, S; Mehta, V; Jahan, SM; Campen, C; Partap, S; Koschmann, C; Monje, M. CNSC-01. GABAERGIC NEURON-TO-GLIOMA SYNAPSES IN DIFFUSE MIDLINE GLIOMAS. Neuro-Oncology. 2023; 25:i11.\n\nBartlett, AL; Zhang, G; Wallace, G; McLean, S; Myers, KC; Teusink-Cross, A; Taggart, C; Patel, B; Davidson, R; Davies, SM; Jodele, S. Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant. Blood Advances. 2023; 7:4555-4562.\n\nBedard, MC; Chihanga, T; Carlile, A; Jackson, R; Brusadelli, MG; Lee, D; VonHandorf, A; Rochman, M; Dexheimer, PJ; Chalmers, J; Lambert, PF; Adam, M; Steven Potter, S; Wells, SI. Single cell transcriptomic analysis of HPV16-infected epithelium identifies a keratinocyte subpopulation implicated in cancer. Nature Communications. 2023; 14:1975.\n\nBender, J; Damodharan, S; Moskop, A; Toner, K; Vatsayan, A; Capitini, C; Baggott, C; Schiff, DE; Katsanis, E; Raikar, SS; Talano, JM; Schultz, LM; Pommert, L. Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas. Journal of Clinical Oncology. 2023; 41:10031.\n\nBender, JD; Oquendo-del Toro, H; Benoit, J; Howell, JC; Badia, P; Davies, SM; Grimley, MS; Jodele, S; Phillips, C; Burns, K; Rose, SR; Hoefgen, H; Khandelwal, P; Myers, KC. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy. 2023; 29:130.e1-130.e8.\n\nBender, JD; Rubinstein, JD; Mizukawa, B; Perentesis, JP; Pommert, L. Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy. Pediatric Blood and Cancer. 2023; 70:e30214.\n\nBennett, J; Ishikawa, C; Agarwal, P; Yeung, J; Sampson, A; Uible, E; Vick, E; Bolanos, LC; Hueneman, K; Wunderlich, M; Rosenbaum, J; Hoyt, SB; Thomas, CJ; Starczynowski, DT. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood. 2023; 142:989-1007.\n\nBetensky, M; Mosha, M; Tarango, C; Anupam, V; Bhat, R; Kucine, N; Nakano, T; Woods, G; Nakar, C; Amankwah, E; Brandão, L; Schulman, S; Goldenberg, N. OC 38.4 Transient Antiphospholipid Antibodies, Antiphospholipid Syndrome and Clinical Outcomes in Patients <21 Years Old with Provoked Venous Thromboembolism: Analysis from the Kids-DOTT Multinational Trial. Research and Practice in Thrombosis and Haemostasis. 2023; 7:100519.\n\nBewersdorf, JP; Xie, Z; Bejar, R; Borate, U; Boultwood, J; Brunner, AM; Buckstein, R; Carraway, HE; Churpek, JE; Daver, NG; Xu, ML; Savona, MR; Wei, AH; Zeidan, AM. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 60:101072.\n\nBilston, L; Uminski, K; Kalfa, TA; Husami, A; Goodyear, MD; Rydz, N. A Novel Beta Globin Frameshift Mutation Causing Autosomal Dominant Beta Thalassemia. Blood. 2023; 142:1105.\n\nBorst, AJ; Hammill, AM; Crary, SE; McLean, TW; Felton, T; Blatt, J. Barriers to Genetic Testing in Vascular Malformations. JAMA Network Open. 2023; 6:e2314829.\n\nBouffi, C; Wikenheiser-Brokamp, KA; Chaturvedi, P; Sundaram, N; Goddard, GR; Wunderlich, M; Brown, NE; Staab, JF; Latanich, R; Zachos, NC; Mulloy, JC; Zorn, AM; Wells, JM; Helmrath, MA. In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice. Nature Biotechnology. 2023; 41:824-831.\n\nBrivio, E; Pennesi, E; Willemse, M; Jiang, Y; van der Velden, V; Beverloo, B; Hudson, C; Kuttschreuter, L; van der Sluis, I; Brethon, B; Locatelli, F; Roth, M; Hijiya, N; Zwaan, M. P676: UPDATED RESULTS FROM THE TRIAL ITCC‐054/COG‐AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA. HemaSphere. 2023; 7:e506783a.\n\nBroder, MS; Adams, DM; Canaud, G; Collins, C; Davis, K; Frieden, IJ; Gibbs, SN; Hammill, AM; Keppler-Noreuil, KM; Nakano, TA; Penington, A; Srivastava, S; Tollefson, MM; Warman, ML. RAND/UCLA Modified Delphi Panel on the Severity, Testing, and Medical Management of PIK3CA-Related Spectrum Disorders (PROS). 2023; 4:e067.\n\nBurke, GA A; Vinti, L; Kabickova, E; Beishuizen, A; Tacyildiz, N; Uyttebroeck, A; Kang, HJ; Luisi, F; Minard-Colin, V; Burkhardt, B; Srinivasan, S; Bhojwani, D; Norris, R; Cairo, M. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial. Blood Advances. 2023; 7:602-610.\n\nButler-Foster, T; Khandelwal, A; Montemayor, C; Miller, YM; Yan, MT S; Holmberg, JA; Ipe, TS; Accooe, P; Cancelas, JA. From MPOX to the next epidemic: Words matter when talking about equity-deserving groups. Transfusion. 2023; 63:646-651.\n\nCantrell, R; Feldman, H; Rosenfeldt, L; Ali, A; Sharma, B; Revenko, A; Monia, B; Waggoner, S; Palumbo, J. PB0727 The Role of Thrombin and Thrombin Signaling in Chronic LCMV Infection. Research and Practice in Thrombosis and Haemostasis. 2023; 7:101315.\n\nCeolan, J; Seu, K; Ntoumaziou, A; Elgammal, Y; Emberesh, S; Bilston, L; Richards, D; Dickerson, KE; Chonat, S; Rydz, N; Lutzko, C; Husami, A; Zhang, W; Kalfa, TA. Erythrocyte Disorders Mimicking Congenital Dyserythropoietic Anemia Based on Bone Marrow Pathology Exposed By Genetic Evaluation. Blood. 2023; 142:2459.\n\nChandrasekaran, P; Han, Y; Zerbe, CS; Heller, T; DeRavin, SS; Kreuzberg, SA; Marciano, BE; Siu, Y; Jones, DR; Abraham, RS; Segre, JA; Bryant, CE; Holland, SM; Falcone, EL. Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease. Journal of Allergy and Clinical Immunology. 2023; 152:1619-1633.e11.\n\nCheng, H; Faughnan, ME; terBrugge, KG; Liu, H; Krings, T; Brain Vascular Malformation Consortium Hereditary , . Prevalence and Characteristics of Intracranial Aneurysms in Hereditary Hemorrhagic Telangiectasia. American Journal of Neuroradiology. 2023; 44:1367-1372.\n\nChlon, TM; Patnaik, MM. Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies. American Journal of Hematology. 2023; 98:1673-1676.\n\nChlon, TM; Stepanchick, E; Sulentic, A; Wilson, A; Starczynowski, DT. Abstract A46: Heterozygous mutations in DDX41 cause erythroid progenitor cell defects and cooperate with p53 mutations to cause hematologic malignancy. 2023; 4:a46.\n\nCochran, AE; Hassan, A; Hueneman, K; Choi, K; Starczynowski, DT. Defective Necroptosis Mediates Chemotherapy Resistance in AML. Blood. 2023; 142:1394.\n\nCohen, C; Powers, J; Tarango, C. Emicizumab Use in Infancy: A Survey of United States Pediatric Hemophilia Treatment Center Medical Directors. Blood. 2023; 142:1242.\n\nCohen-Cutler, S; Blatt, J; Bayliff, S; Iacobas, I; Hammill, A; Sisk, BA. Vascular Anomalies Care in the United States: A Cross-Sectional National Survey. The Journal of Pediatrics. 2023; 261:113579.\n\nColeman, KD; McKinley, K; Ellison, AM; Alpern, ER; Hariharan, S; Topoz, I; Wurtz, M; Nielsen, B; Cook, LJ; Morris, CR; King, AA; Baumann, A; Frankenberger, W; Brousseau, DC. Return visit rates after an emergency department discharge for children with sickle cell pain episodes. Pediatric Blood and Cancer. 2023; 70:e30553.\n\nColeman, KD; McKinley, K; Ellison, AM; Alpern, ER; Hariharan, S; Topoz, I; Wurtz, M; Nielsen, B; Cook, LJ; Morris, CR; King, AA; Baumann, A; Frankenberger, W; Brousseau, DC. Association between Acute Pain Scores in Children with Sickle Cell Disease and Emergency Department Disposition and Return Visit Rates. Blood. 2023; 142:3874.\n\nCooke-Barber, J; Brungardt, JG; Sorger, M; Pressey, JG; Turpin, B; Nagarajan, R; Szabo, S; Sorger, J; Johnson, N; Dasgupta, R. ASO Author Reflections: Minimizing Time in Hospital via Bone Biopsy or Other Means. Annals of Surgical Oncology. 2023; 30:3666.\n\nCooke-Barber, J; Brungardt, JG; Sorger, M; Pressey, JG; Turpin, B; Nagarajan, R; Szabo, S; Sorger, J; Johnson, N; Dasgupta, R. Pediatric and Young Adult Image-Guided Percutaneous Bone Biopsy-A New Standard of Care?. Annals of Surgical Oncology. 2023; 30:3658-3665.\n\nCoppola, T; Perrone, O; Batram, J; Nasr, W; Treichel, S; Xu, J; Myers, K; Filippi, M. Human Hematopoietic Stem Cells Have Altered Mitochondrial Activity after Stem Cell Transplantation. Blood. 2023; 142:3430.\n\nCrosby, LE; Lang, A; Mara, C; Quinn, CT; Schultz, CL; Bear, B; Akintobi, TE; Miller, RE; Hildenbrand, AK. Patterns of Nonadherence to Hydroxyurea in Pediatric Sickle Cell Disease. Blood. 2023; 142:7198.\n\nCullion, K; Ostertag-Hill, CA; Pan, M; Timko, B; Boscolo, E; Kohane, DS. Ablation of Venous Malformations by Photothermal Therapy with Intravenous Gold Nanoshells. Nano Letters: a journal dedicated to nanoscience and nanotechnology. 2023; 23:7092-7099.\n\nD’Alessandro, PR. Research-Based Theater in the Pediatric Oncology Setting: Balancing Ethical Tensions. Qualitative Inquiry. 2023; 29:305-313.\n\nDandamudi, A; Akbar, H; Cancelas, J; Zheng, Y. Rho GTPase Signaling in Platelet Regulation and Implication for Antiplatelet Therapies. International Journal of Molecular Sciences. 2023; 24:2519.\n\nDandamudi, A; Seibel, W; Tourdot, B; Cancelas, JA; Akbar, H; Zheng, Y. Structure-Activity Relationship Analysis of Rhosin, a RhoA GTPase Inhibitor, Reveals a New Class of Antiplatelet Agents. International Journal of Molecular Sciences. 2023; 24:4167.\n\nDandoy, CE; Tsong, WH; Sarikonda, K; McGarvey, N; Perales, MA. Systematic Review of Signs and Symptoms Associated with Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Transplantation and cellular therapy. 2023; 29:282.e1-282.e9.\n\nDaugherty, EC; Mascia, A; Zhang, Y; Lee, E; Xiao, Z; Sertorio, M; Woo, J; McCann, C; Russell, K; Levine, L; Bradley, J; Simone, CB; Perentesis, J; Breneman, J. FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study. JMIR Research Protocols. 2023; 12:e41812.\n\nde Blank, P; Nishiyama, A; López-Juárez, A. A new era for myelin research in Neurofibromatosis type 1. Glia. 2023; 71:2701-2719.\n\nDean, ST; Ishikawa, C; Zhu, X; Walulik, S; Nixon, T; Jordan, JK; Henderson, S; Wyder, M; Salomonis, N; Wunderlich, M; Greis, KD; Starczynowski, DT; Volk, AG. Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood Advances. 2023; 7:4822-4837.\n\nDeng, L; Costa, F; Blake, KJ; Choi, S; Chandrabalan, A; Yousuf, MS; Shiers, S; Dubreuil, D; Vega-Mendoza, D; Rolland, C; Price, TJ; Ramachandran, R; Horswill, AR; Chiu, IM. S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis. Cell. 2023; 186:5375-5393.e25.\n\nDoherty, AC; Huddleston, DA; Horn, PS; Ratner, N; Simpson, BN; Schorry, EK; Aschbacher-Smith, L; Prada, CE; Gilbert, DL. Motor Function and Physiology in Youth With Neurofibromatosis Type 1. Pediatric Neurology. 2023; 143:34-43.\n\nDong, M; Ware, RE; Dallmann, A; Vinks, AA. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023; 43:419-429.\n\nDourson, AJ; Fadaka, AO; Warshak, AM; Paranjpe, A; Weinhaus, B; Queme, LF; Hofmann, MC; Evans, HM; Donmez, OA; Forney, C; Weirauch, MT; Kottyan, LT; Lucas, D; Deepe, GS; Jankowski, MP. Macrophage epigenetic memories of early life injury drive neonatal nociceptive priming. 2023; 4:2023.02.13.528015.\n\nDunseath, C; O'Connor, G; Mahulkar, S; Badia, P; Koo, J; Dandoy, CE. Incidence of Bloodstream Infections after Hematopoietic Stem Cell Transplantation for Hurler Syndrome. Transplantation and cellular therapy. 2023; 29:707.e1-707.e4.\n\nDvorak, CC; Haddad, E; Heimall, J; Dunn, E; Cowan, MJ; Pai, SY; Kapoor, N; Satter, LF; Buckley, RH; O'Reilly, RJ; Pulsipher, MA; Griffith, LM; Notarangelo, LD; Puck, JM. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions. Journal of Allergy and Clinical Immunology. 2023; 151:547-555.e5.\n\nEarley, EJ; Kelly, S; Fang, F; Alencar, CS; Rodrigues, DD O W; Soares Cruz, DT; Flanagan, J; Ware, RE; Zhang, X; Gordeuk, V; Sabino, E; Custer, B; Dinardo, C; Page, GP. Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. British Journal of Haematology. 2023; 201:343-352.\n\nEldem, I; Picarsic, J; Kumar, A; Mossé, YP; Roberts, KF; Armstrong, AE; Sisk, BA. Lorlatinib use in an infant with thalamic ALK-positive histiocytosis. Pediatric Blood and Cancer. 2023; 70:e30378.\n\nElgamal, OA; Zapata, JC; Li, H; Sharpe, C; Fobare, S; Stearns, B; Lerma, JR; Bryant, K; Furby, C; Long, M; Burd, A; Pauza, CD; Hertlein, EK; Byrd, JC. Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML. Blood. 2023; 142:1544.\n\nElgammal, Y; Risinger, M; Husami, A; Walden, J; Gupta, S; Shah, NC; Boyer, J; Abajas, YL; Winstead, M; Miller, DW; Lorsbach, R; Zhang, W; Kalfa, TA; Niss, O. Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR). Blood. 2023; 142:1079.\n\nEngel, ER; Hammill, A; Adams, D; Phillips, RJ; Jeng, M; Tollefson, MM; Iacobas, I; Schiff, D; Greenberger, S; Kelly, M; Drolet, B; Geddis, A; Goldenberg, D; Ricci, K. Response to sirolimus in capillary lymphatic venous malformations and associated syndromes: Impact on symptomatology, quality of life, and radiographic response. Pediatric Blood and Cancer. 2023; 70:e30215.\n\nFan, C; Wunderlich, M; Cai, X; Yan, Z; Zhang, F; Davis, AK; Xu, L; Guo, F; Lu, QR; Azam, M; Tian, W; Zheng, Y. Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor. Leukemia. 2023; 37:2073-2081.\n\nFarooqui, Z; Johnston, M; Schepers, E; Brewer, N; Hartman, S; Jenkins, T; Bondoc, A; Pai, A; Geller, J; Tiao, GM. Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma. Children. 2023; 10:890.\n\nFenchel, L; Jackson, F; Walker, B; Manuel, C; Hooks, D; Allen, T; Thant, MM; Karkoska, K; Smart, LR; Joffe, NE; Niss, O. Improving Transition of Emerging Adults with Sickle Cell Disease to Adult Care through a Multidisciplinary Process: The Development of a Transition Clinic to Support Transition Success. Blood. 2023; 142:5055.\n\nFichter, KM; Setayesh, T; Malik, P. Strategies for precise gene edits in mammalian cells. Molecular Therapy-Nucleic Acids. 2023; 32:536-552.\n\nFilippi, MD. The multifaceted role of mitochondria in HSC fate decisions: energy and beyond. Experimental Hematology. 2023; 128:19-29.\n\nForlenza, CJ; Rosenzweig, J; Mauguen, A; Buhtoiarov, I; Cuglievan, B; Dave, H; Deyell, RJ; Flerlage, JE; Franklin, AK; Krajewski, J; Willen, F; Yan, AP; Harker-Murray, PD; Giulino-Roth, L. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances. 2023; 7:3225-3231.\n\nGalletta, TJ; Dong, M; Vinks, AA; Chiang, SC C; Teusink-Cross, A; Marsh, RA; Davies, SM; Mehta, PA; Khandelwal, P. 356 Children Under 2 Years Old Treated with Ruxolitinib for Acute and Chronic Graft-Versus-Host-Disease Demonstrate Variable Pharmacokinetics. Transplantation and cellular therapy. 2023; 29:s271-s272.\n\nGalletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; Davies, SM; Grimley, MS; Rubinstein, JD. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Transplantation and cellular therapy. 2023; 29:305-310.\n\nGalletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Pediatric Blood and Cancer. 2023; 70:e30271.\n\nGarland, K; Mullins, E; Bercovitz, RS; Rodriguez, V; Connors, J; Sokkary, N. Hemostatic considerations for gender affirming care. Thrombosis Research. 2023; 230:126-132.\n\nGarrett, MC; Albano, R; Carnwath, T; Elahi, L; Behrmann, CA; Pemberton, M; Woo, D; O’Brien, E; VanCauwenbergh, B; Perentesis, J; Roskin, K; Kornblum, H; Plas, DR; Lu, QR. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma. Scientific Reports. 2023; 13:12433.\n\nGeerlinks, AV; Scull, B; Krupski, C; Fleischmann, R; Pulsipher, MA; Eapen, M; Connelly, JA; Bollard, CM; Pai, SY; Duncan, CN; Jordan, MB; Man, TK; Allen, CE; Marsh, RA. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT. Blood Advances. 2023; 7:3725-3734.\n\nGonzalez, LS; Fisher, AA; D'souza, SP; Cotella, EM; Lang, RA; Robinson, JE. Ventral striatum dopamine release encodes unique properties of visual stimuli in mice. eLife. 2023; 12:e85064.\n\nGonzalez-Muñoz, T; Giannatale, AD; García-Silva, S; Santos, V; Sanchez-Redondo, S; Savini, C; Graña-Castro, O; Blanco-Aparicio, C; Fischer, S; De Wever, O; Ratner, N; Yohay, K; Theuer, CP; Peinado, H. Endoglin, a Novel Biomarker and Therapeutical Target to Prevent Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis. Clinical Cancer Research. 2023; 29:3744-3758.\n\nGorak, EJ; Otterstatter, M; Al Baghdadi, T; Gillis, N; Foran, JM; Liu, JJ; Bejar, R; Gore, SD; Kroft, SH; Harrington, A; Walker, ME; Padron, E; DeZern, AE; Sekeres, MA. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Advances. 2023; 7:6120-6129.\n\nGossai, N; Bhojwani, D; Schafer, ES; Chang, BH; Pommert, L; Verma, A; Malvar, J; Chi, YY; Hitzler, J; Burke, MJ; Rabin, KR. Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023; 37:1138-1140.\n\nGounder, M; Ratan, R; Alcindor, T; Schöffski, P; Van Der Graaf, WT; Wilky, BA; Riedel, RF; Lim, A; Smith, LM; Moody, S; Philip, T; Pressey, JG; Kummar, S; Kasper, B. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. The New England journal of medicine. 2023; 388:898-912.\n\nGrimley, M; Maron, G; Gomez, CA; Prasad, VK; Dara, J; Papanicolaou, GA; Fukushima, K; Wynn, RF; Boeckh, M. Preliminary Results of a Phase 2a Clinical Trial to Evaluate Safety, Tolerability and Antiviral Activity of Intravenous Brincidofovir (BCV IV) in Immunocompromised Patients with Adenovirus Infection. Blood. 2023; 142:112.\n\nGrover, SP; Bharathi, V; Posma, JJ; Griffin, JH; Palumbo, JS; Mackman, N; Antoniak, S. Thrombin-mediated activation of PAR1 enhances doxorubicin-induced cardiac injury in mice. Blood Advances. 2023; 7:1945-1953.\n\nGurska, LM; Okabe, R; Schurer, A; Tong, MM; Soto, M; Choi, D; Ames, K; Glushakow-Smith, S; Montoya, A; Tein, E; Levine, RL; Goel, S; Halmos, B; Gritsman, K. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical Cancer Research. 2023; 29:943-956.\n\nGuzman-Gomez, A; Ahmed, HF; Dani, A; Zafar, F; Lehenbauer, DG; Potter, AS; Morales, DL S; Ziady, AG; Hayes, D. Center volume effect on acute cellular rejection and outcomes in pediatric lung transplant recipients. Journal of Heart and Lung Transplantation. 2023; 42:1030-1039.\n\nGuzman-Gomez, A; Skala, E; Dani, A; Sharma, N; Ziady, A; Hayes, D. Sex and Sex Hormones Matter in Lung Transplant Outcomes. Journal of Heart and Lung Transplantation. 2023; 42:s141.\n\nHan, L; Dong, L; Leung, K; Zhao, Z; Li, Y; Gao, L; Chen, Z; Xue, J; Qing, Y; Li, W; Wei, M; Su, R; Chen, J; Deng, X. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 2023; 30:52-68.e13.\n\nHashimoto, M; Li, J; Andreassen, PR; Huang, G. CPT1a Controls the Function of Long-Term Hematopoietic Stem Cells By Regulating the Balance between Fatty Acid Oxidation and Oxphos in Mitochondria. Blood. 2023; 142:4089.\n\nHayes, D; Dani, A; Guzman-Gomez, A; Zafar, F; Morales, DL S; Ziady, AG. Changing racial and ethnic differences for lung transplantation in cystic fibrosis. Pediatric Transplantation. 2023; 27:e14404.\n\nHeczey, A; Xu, X; Courtney, AN; Tian, G; Barragan, GA; Guo, L; Amador, CM; Ghatwai, N; Rathi, P; Wood, MS; Sachar, C; Wells, DK; Dotti, G; Metelitsa, LS. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nature Medicine. 2023; 29:1379-1388.\n\nHegde, S; Nestheide, S; Wellndorf, A; Zheng, Y; Cancelas, J. 3080 – RHOA SIGNALING IS REQUIRED FOR THE COLD-INDUCED PLATELET LESION AND REVERSIBLE TARGETING OF RHOA IN A NEW PLATELET ADDITIVE SOLUTION EXTENDS DONOR-DERIVED PLATELET SHELF-LIFE TO FOURTEEN DAYS. Experimental Hematology. 2023; 124:s90.\n\nHennigan, RF; Thomson, CS; Stachowski, K; Nassar, N; Ratner, N. Merlin tumor suppressor function is regulated by PIP2-mediated dimerization. Editor, van der Wel P. PloS one. 2023; 18:e0281876.\n\nHernández, G; Romero-Cortadellas, L; Ferrer-Cortès, X; Venturi, V; Dessy-Rodriguez, M; Olivella, M; Husami, A; de Soto, CP; Morales-Camacho, RM; Villegas, A; Pérez-Montero, S; Tornador, C; Segovia, JC; Sánchez, M. Mutations in the RACGAP1 gene cause autosomal recessive congenital dyserythropoietic anemia type III. Haematologica: the hematology journal. 2023; 108:581-587.\n\nHildenbrand, AK; Kidwell, KM; McGrady, ME; Quinn, CT; Crosby, LE; Mara, CA. Feasibility of Electronic Medication Monitoring Among Adolescents and Emerging Adults with Sickle Cell Disease. Patient Preference and Adherence. 2023; 17:3167-3171.\n\nHines, MR; Knight, TE; McNerney, KO; Leick, MB; Jain, T; Ahmed, S; Frigault, MJ; Hill, JA; Jain, MD; Johnson, WT; Frey, NV; Teachey, DT; Frank, MJ; Shah, NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplantation and cellular therapy. 2023; 29:438.e1-438.e16.\n\nHu, X; Wu, X; Berry, K; Zhao, C; Xin, D; Ogurek, S; Liu, X; Zhang, L; Luo, Z; Sakabe, M; Lee, L; Hu, M; Xin, M; Lu, QR. Nuclear condensates of YAP fusion proteins alter transcription to drive ependymoma tumourigenesis. Nature Cell Biology. 2023; 25:323-336.\n\nHudda, Z; Myers, KC. Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?. Hematology-American Society of Hematology Education Program. 2023; 2023:141-148.\n\nHudock, KM; Collins, MS; Imbrogno, MA; Kramer, EL; Brewington, JJ; Ziady, A; Zhang, N; Snowball, J; Xu, Y; Carey, BC; Gollomp, K; Mangalmurti, N; Trapnell, BC; Clancy, JP. Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier function. Frontiers in Immunology. 2023; 13:1023553.\n\nHulbert, ML; Manwani, D; Meier, ER; Alvarez, OA; Brown, RC; Callaghan, MU; Campbell, AD; Coates, TD; Frei-Jones, MJ; Hankins, JS; Shah, N; Smith-Whitley, K; Thornburg, C; Kanter, J. Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center. Pediatric Blood and Cancer. 2023; 70:e29961.\n\nHunt, BG; Davis, JC; Fox, LH; Vicente-Muñoz, S; Lester, C; Wells, SI; Waltz, SE. RON-augmented cholesterol biosynthesis in breast cancer metastatic progression and recurrence. Oncogene: Including Oncogene Reviews. 2023; 42:1716-1727.\n\nIshikawa, C; Barreyro, L; Sampson, A; Hueneman, K; Choi, K; Bolanos, LC; Volk, A; Watowich, SS; Greis, K; Starczynowski, DT. UBE2N Regulates Oncoprotein Networks in Myeloid Malignancies. Blood. 2023; 142:2762.\n\nIsmail, M; Craig, S; Ahmed, R; de Blank, P; Tiwari, P. Opportunities and Advances in Radiomics and Radiogenomics for Pediatric Medulloblastoma Tumors. Diagnostics. 2023; 13:2727.\n\nJackson, M; Ahmari, N; Wu, J; Rizvi, TA; Fugate, E; Kim, MO; Dombi, E; Arnhof, H; Boehmelt, G; Düchs, MJ; Long, CJ; Maier, U; Trapani, F; Hofmann, MH; Ratner, N. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. The Journal of pharmacology and experimental therapeutics. 2023; 385:106-116.\n\nJD, B; H, OT; J, B; JC, H; P, B; SM, D; MS, G; S, J; C, P; K, B; SR, R; H, H; P, K; KC, M. Reduced-intensity conditioning mitigates risk for primary ovarian insufficiency but does not decrease risk for infertility in pediatric and young adult survivors of hematopoietic stem cell transplantation. 2023.\n\nJenkins, AM; Weber, DE; Arfaa, JJ E; Arken, A; Clark, DL; Dobbs, E; Lahbabi, B; Myers, K; Tu, J; Clarke-Myers, K. Using participatory research to identify actionable facilitators and barriers to effective inpatient interdisciplinary communication. Journal of hospital medicine (Online). 2023; 18:130-138.\n\nJodele, S; Mizuno, K; Sabulski, A; Vinks, AA. Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies. Clinical Pharmacology and Therapeutics. 2023; 114:511-514.\n\nJodele, S; Sabulski, A. Reeling in complement in transplant-associated thrombotic microangiopathy: You're going to need a bigger boat. American Journal of Hematology. 2023; 98 Suppl 4:S57-S73.\n\nJohnston, ME; Farooqui, ZA; Nagarajan, R; Pressey, JG; Turpin, B; Dasgupta, R. Fluorescent-guided surgery and the use of indocyanine green sentinel lymph node mapping in the pediatric and young adult oncology population. Cancer. 2023; 129:3962-3970.\n\nJosselsohn, R; Barnes, BJ; Kalfa, TA; Blanc, L. Navigating the marrow sea towards erythromyeloblastic islands under normal and inflammatory conditions. Current Opinion in Hematology. 2023; 30:80-85.\n\nJosselsohn, R; Vagrecha, A; LaPan, M; Papoin, J; Kamen, J; Cho, YM; Rao, R; Romano, L; Salomonis, N; Kalfa, TA; Blanc, L; Barnes, BJ. Irf5 Expression in Macrophages Contributes to Iron Regulation within Erythromyeloblastic Islands. Blood. 2023; 142:920.\n\nJuckett, M; Dandoy, C; DeFilipp, Z; Kindwall-Keller, TL; Spellman, SR; Ustun, C; Waldman, BM; Weisdorf, DJ; Wood, WA; Horowitz, MM; Burns, LJ; Khera, N. How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy?. Blood Reviews. 2023; 60:101079.\n\nKahn, SR; Arnold, DM; Casari, C; Desch, KC; Devreese, KM J; Favaloro, EJ; Gaertner, F; Gouw, SC; Gresele, P; Griffioen, AW; Violi, F; Weyand, AC; Williams, S; Zheng, Z. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress. Research and Practice in Thrombosis and Haemostasis. 2023; 7:100193.\n\nKatayama, KI; Zheng, Y; Inoue, N. Rac is required for the survival of cortical neurons. Experimental Neurology. 2023; 361:114316.\n\nKhandelwal, P; Lounder, DT; Bartlett, A; Haberman, Y; Jegga, AG; Ghandikota, S; Koo, J; Luebbering, N; Leino, D; Abdullah, S; Karns, R; Nelson, AS; Denson, LA; Davies, SM. Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease. Haematologica: the hematology journal. 2023; 108:1803-1816.\n\nKilian, A; Latino, GA; White, AJ; Ratjen, F; McDonald, J; Whitehead, KJ; Gossage, JR; Krings, T; Lawton, MT; Kim, H; Faughnan, ME; The Brain Vascular Malformation Consortium Hht Inv, . Comparing Characteristics and Treatment of Brain Vascular Malformations in Children and Adults with HHT. Journal of Clinical Medicine. 2023; 12:2704.\n\nKim, TO; Geris, JM; Grimes, AB; Grace, RF; Lambert, MP; Rose, MJ; Shimano, KA; Niss, O; Neunert, C; Nakano, TA; Kirk, SE; Despotovic, JM; Flanagan, JM; Scheurer, ME. Genetic Variants in Canonical Wnt Signaling Pathway Associated with Pediatric ITP. Blood. 2023; 142:2593.\n\nKleman, A; Singavi, A; Pommert, L; Mathison, AJ; Hari, P; Dhakal, B; Mohan, M; Janz, S; Knight, JM; Shah, MV; Schinke, C; Burns, R; Steinhardt, GF; Rao, S; Carlson, K. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy. Blood Advances. 2023; 7:5549-5553.\n\nKnight, TE; Ahn, KW; Hebert, KM; Atshan, R; Wall, DA; Chiengthong, K; Lund, TC; Prestidge, T; Rangarajan, HG; Dvorak, CC; Qayed, M; Broglie, L; Eapen, M; Yanik, GA. No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplantation. 2023; 58:1390-1393.\n\nKnight, TE; Ahn, KW; Hebert, KM; Atshan, R; Wall, DA; Chiengthong, K; Rotz, SJ; Fraint, E; Rangarajan, HG; Auletta, JJ; Qayed, M; Broglie, L; Eapen, M; Yanik, GA. Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors. Transplantation and cellular therapy. 2023; 29:380.e1-380.e9.\n\nKoh, W; Zang, H; Ollberding, NJ; Ziady, A; Hayes, D. Extracorporeal membrane oxygenation bridge to pediatric lung transplantation: Modern era analysis. Pediatric Transplantation. 2023; 27:e14570.\n\nKoo, DJ; Reynaud, D; Ziady, A; Kahn, S; Abdullah, S; Luebbering, N; Strecker, L; Lake, KE; Giordullo, L; Ibrahimova, A; Good, S; Dandoy, DC E; Myers, K; Jodele, S; Davies, SM. 166 Reduced Sphingosine-1-Phosphate Leads to Hypoxemia and Lung Injury after Hematopoietic Stem Cell Transplant. Transplantation and cellular therapy. 2023; 29:s134.\n\nKoo, J; Grom-Mansencal, I; Howell, JC; Rios, JM; Mehta, PA; Davies, SM; Myers, KC. Gonadal function in pediatric Fanconi anemia patients treated with hematopoietic stem cell transplant. Haematologica: the hematology journal. 2023; 108:2358-2368.\n\nKoo, J; Ziady, AG; Reynaud, D; Abdullah, S; Luebbering, N; Kahn, S; Langenberg, L; Strecker, L; Lake, K; Dandoy, CE; Siefert, ME; Skala, E; Jodele, S; Davies, SM. Increased Body Mass Index Augments Endothelial Injury and Clinical Outcomes after Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy. 2023; 29:704.e1-704.e8.\n\nLane, A. Efficiency of observed information adaptive designs in linear models. Journal of Statistical Planning and Inference. 2023; 223:63-74.\n\nLanzkron, S; Manwani, D; Kanter, J; Sinha, AA; Miller, RE; Cronin, R; Jacob, SA; Harper, J; Anderson, AR; Treadwell, M; Saif Ur Rehman, S; Shook, LM; Frei-Jones, M; Little, JA. Grndad and Disease Modifying Therapy (DMT): Shifts in Dmt Are Seen at the Adolescent/Young Adult Transition in Sickle Cell Disease in a Multi-Site Prospective Registry. Blood. 2023; 142:798.\n\nLaranjeira, AB A; Kong, T; Snyder, SC; Fulbright, MC; Fisher, DA C; Starczynowski, DT; Oh, ST. In Vivo Ablation of NFκB Cascade Effectors Alleviates Disease Burden in Myeloproliferative Neoplasms. Blood. 2023; 142:991.\n\nLazow, M; Baxter, P; Stanek, J; Rodriguez, D; Kumar, SS; Palmer, J; Leach, J; Mikael, L; Thomas, D; Fuller, C; Stewart, C; Mardis, E; Fouladi, M; Drissi, R. DIPG-54. UPDATED FINDINGS FROM THE PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY-DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT). Neuro-Oncology. 2023; 25:i25-i26.\n\nLazow, M; Palmer, J; Stanek, J; Baxter, P; Thomas, D; Salloum, R; de Blank, P; Mikael, L; Kumar, SS; Leonard, J; Mardis, E; Drissi, R; Fouladi, M; Rodriguez, D. DIPG-52. EXTRAPONTINE PROGRESSION WITH STABLE PONTINE DISEASE POST-RADIOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) ON A CONNECT TRIAL: IMPLICATIONS FOR RADIATION TREATMENT VOLUMES. Neuro-Oncology. 2023; 25:i25.\n\nLazow, MA; Salloum, R; Pressey, JG. Comorbidity Burden in a Cohort of Adolescent and Young Adult Patients Diagnosed with Central Nervous System Tumors and Sarcomas. Journal of Adolescent and Young Adult Oncology. 2023; 12:215-223.\n\nLeBlanc, F; Bennett, J; Choi, K; Starczynowski, DT. Targeting CREB-Binding Protein (CREBBP) Overcomes Resistance to Azacitidine and Venetoclax Therapy in Acute Myeloid Leukemia (AML). Blood. 2023; 142:5765.\n\nLeiding, JW; Arnold, DE; Parikh, S; Logan, B; Marsh, RA; Griffith, LM; Wu, R; Kidd, S; Mallhi, K; Chellapandian, D; Pulsipher, MA; Torgerson, TR; Malech, HL; Kang, EM. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. 2023; 142:2105-2118.\n\nLeiding, JW; Vogel, TP; Santarlas, VG J; Mhaskar, R; Smith, MR; Carisey, A; Vargas-Hernández, A; Silva-Carmona, M; Heeg, M; Rensing-Ehl, A; Szabolcs, P; Velasco, H; Warnatz, K; Walkovich, K. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome. Journal of Allergy and Clinical Immunology. 2023; 151:1081-1095.\n\nLerman, BJ; Li, Y; Carlowicz, C; Granger, M; Cash, T; Sadanand, A; Somers, K; Ranavaya, A; Weiss, BD; Choe, M; Macy, ME; Shusterman, S; Federico, SM; Bagatell, R. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. Journal of Clinical Oncology. 2023; 41:508-516.\n\nLi, J; Malouf, C; Miles, LA; Willis, MB; Pietras, EM; King, KY. Chronic inflammation can transform the fate of normal and mutant hematopoietic stem cells. Experimental Hematology. 2023; 127:8-13.\n\nLi, J; Wu, Y; Xue, T; He, J; Zhang, L; Liu, Y; Zhao, J; Chen, Z; Xie, M; Xiao, B; Liu, N; Guo, F; Zhang, L; Zhang, L. Cdc42 signaling regulated by dopamine D2 receptor correlatively links specific brain regions of hippocampus to cocaine addiction. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2023; 1869:166569.\n\nLi, Y; Martin, TE; Hancock, JM; Li, R; Viswanathan, S; Lydon, JP; Zheng, Y; Ye, X. Visualization of preimplantation uterine fluid absorption in mice using Alexa Fluor™ 488 Hydrazide†. Biology of Reproduction. 2023; 108:204-217.\n\nLi, Y; Xue, M; Deng, X; Dong, L; Nguyen, LX T; Ren, L; Han, L; Li, C; Xue, J; Zhao, Z; Tian, J; Shen, B; Su, R; Chen, J. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 2023; 30:1072-1090.e10.\n\nLin, Y; Zhao, X; Liou, B; Fannin, V; Zhang, W; Liu, Y; Wang, X; Pan, D; Grabowski, G; Liu, C; Sun, Y. Earlier-onset, more severe neurodegeneration in PGRN KO mice with a decreased dose of D409V Gba1. Molecular Genetics and Metabolism. 2023; 138:107207.\n\nLin, Y; Zheng, Y. Rho Family GTPases and their Modulators. NADPH Oxidases Revisited: From Function to Structure. : Springer Nature; Springer Nature; 2023.\n\nLipsitt, A; Marón, GM; Agarwal, N; Albert, J; Boelens, J; Buchbinder, D; Chavan, R; Dallas, R; Dandoy, DC E; Eisenman, D; Sharma, A; Su, Y; Tang, L; Sharma, A. 426 Impact of Trimethoprim/Sulfamethoxazole Prophylaxis on Engraftment in Pediatric Hematopoietic Cell Transplant Recipients. Transplantation and cellular therapy. 2023; 29:s322-s323.\n\nLittner, L; Thomas, E; Doyle, J; Hendrickson, J; Adkins, S; Mooney, L; Tarango, C. Improving bleeding disorder treatment log adherence: An application of the information-motivation-behavioral skills model. Haemophilia. 2023; 29:180-185.\n\nLiu, X; Sato, N; Yabushita, T; Li, J; Jia, Y; Tamura, M; Asada, S; Fujino, T; Fukushima, T; Yonezawa, T; Shibata, T; Miyake, K; Kitamura, T; Goyama, S. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Molecular Medicine. 2023; 15:e15631.\n\nLivnat, G; Meeker, JD; Ostmann, AJ; Strecker, LM; Clancy, JP; Brewington, JJ. Phenotypic Alteration of an Established Human Airway Cell Line by Media Selection. International Journal of Molecular Sciences. 2023; 24:1246.\n\nLiy-Wong, C; Tarango, C; Pope, E; Coates, T; Bruckner, AL; Feinstein, JA; Schwieger-Briel, A; Hubbard, LD; Jane, C; Torres-Pradilla, M; Zmazek, M; Lara-Corrales, I. Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa. Orphanet Journal of Rare Diseases. 2023; 18:38.\n\nLu, R; Luo, Z. MDB-02. NUCLEAR ENVELOPE PHOSPHATASE CTDNEP1 MUTATIONS POTENTIATE AGGRESSIVE MEDULLOBLASTOMA BY TRIGGERING MYC ACTIVATION AND GENOMIC INSTABILITY. Neuro-Oncology. 2023; 25:i61-i62.\n\nLuo, Z; Lu, R. MDB-05. HUMAN FETAL CEREBELLAR CELL ATLAS INFORMS MEDULLOBLASTOMA ORIGIN AND ONCOGENESIS. Neuro-Oncology. 2023; 25:i62.\n\nLuo, Z; Xin, D; Liao, Y; Berry, K; Ogurek, S; Zhang, F; Zhang, L; Zhao, C; Rao, R; Dong, X; Zhou, W; Weiss, WA; Andreassen, P; Lu, QR. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. Nature Communications. 2023; 14:762.\n\nMagallón-Lorenz, M; Terribas, E; Ortega-Bertran, S; Creus-Bachiller, E; Fernández, M; Requena, G; Rosas, I; Mazuelas, H; Uriarte-Arrazola, I; Negro, A; Reuss, D; Carrió, M; Gel, B; Serra, E. Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis. iScience. 2023; 26:106096.\n\nMarasligiller, SA; Williams, BK; Vadivelu, S; Correa, ZM; Abruzzo, TA; Nicola, MD; Lane, A; Geller, JI. Ocular survival after intra-arterial chemotherapy for retinoblastoma improves with accrual of experience and programmatic evolution. Pediatric Blood and Cancer. 2023; 70:e30071.\n\nMaria, NI; Papoin, J; Raparia, C; Sun, Z; Josselsohn, R; Lu, A; Katerji, H; Syeda, MM; Polsky, D; Paulson, R; Kalfa, T; Barnes, BJ; Zhang, W; Blanc, L; Davidson, A. Human TLR8 induces inflammatory bone marrow erythromyeloblastic islands and anemia in SLE-prone mice. Life Science Alliance. 2023; 6:e202302241.\n\nMarion, W; Koppe, T; Chen, CC; Wang, D; Frenis, K; Fierstein, S; Sensharma, P; Aumais, O; Peters, M; Ruiz-Torres, S; Ebert, BL; Starczynowski, D; da Rocha, EL; Rowe, RG. RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia. Leukemia. 2023; 37:1698-1708.\n\nMascia, AE; Daugherty, EC; Zhang, Y; Lee, E; Xiao, Z; Sertorio, M; Woo, J; Backus, LR; McDonald, JM; McCann, C; Bradley, JD; Simone, CB; Perentesis, JP; Breneman, JC. Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial. JAMA oncology. 2023; 9:62-69.\n\nMatsui, S; Ri, C; Bolanos, LC; Choi, K; Shibamiya, A; Ishii, A; Takaishi, K; Oshima-Hasegawa, N; Tsukamoto, S; Takeda, Y; Mimura, N; Yokote, K; Starczynowski, DT; Sakaida, E; Muto, T. Regulation of Metabolic Homeostasis By TRAF6 Contributes to the Leukemia Progression. Blood. 2023; 142:1370.\n\nMcDaniel, CG; Adams, DM; Steele, KE; Hammill, AM; Merrow, AC; Crane, JL; Smith, CL; Kozakewich, HP W; Le Cras, TD. Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment. Pediatric Blood and Cancer. 2023; 70:e30219.\n\nMcDonald, CL; Qasba, P; Anderson, DG; Bao, G; Colvin, RA; Kohn, DB; Malik, P; Mitchell, MJ; Pu, WT; Rawlings, DJ; Williams, DA; Flotte, TR. Future Directions and Resource Needs for National Heart, Lung, and Blood Institute (NHLBI) Gene Therapy Research: A Report of an NHLBI Workshop. Human Gene Therapy. 2023; 34:83-89.\n\nMcElhinney, K; Smart, LR; Howard, TA; Power-Hays, A; Ware, RE. A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay. Blood. 2023; 142:2530.\n\nMcGrady, ME; Ketterl, TG; Norris, RE; Perentesis, JP; Pettee, D; Mara, CA; Breen, G; Pai, AL H. Barriers to medication adherence among adolescents and young adults with cancer. Pediatric Blood and Cancer. 2023; 70:e30186.\n\nMcLean, TW; Borst, AJ; Hammill, AM; Iacobas, I; Atkinson, A; Shah, T; Margolin, JF; Bayliff, SL; Blatt, J. Practice Variations in Managing Infantile Hemangiomas. Journal of Pediatric Hematology/Oncology. 2023; 45:452-460.\n\nMcNerney, KO; Lim, SS; Miller, A; Amankwah, E; Dreyzin, A; Vatsayan, A; Hermiston, M; Baggott, C; Prabhu, S; Pacenta, HL; Curran, KJ; Mackall, C; Laetsch, TW; Schultz, LM. 262 High Disease Burden and Severe Neutropenia Predict HLH Toxicity in Patients with B-Acute Lymphoblastic Leukemia (B-ALL) Treated with Tisagenlecleucel in the PRWCC. Transplantation and cellular therapy. 2023; 29:s202-s203.\n\nMenéndez-Gutiérrez, MP; Porcuna, J; Nayak, R; Paredes, A; Niu, H; Núñez, V; Paranjpe, A; Gómez, MJ; Bhattacharjee, A; Schnell, DJ; Sánchez-Cabo, F; Welch, JS; Salomonis, N; Cancelas, JA; Ricote, M. Retinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis. Blood. 2023; 141:592-608.\n\nMerjaneh, N; Kim, H; Escoto, H; Metts, J; Ray, A; Bukowinski, A; Leblanc, Z; Fair, D; Watanbe, M; Alva, E; Hartt, D; Cramer, SL; Szabo, S; Pressey, JG. Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations. Journal of Pediatric Hematology/Oncology. 2023; 45:315-321.\n\nMilne, P; Bomken, S; Slater, O; Kumar, A; Nelson, A; Roy, S; Velazquez, J; Mankad, K; Nicholson, J; Yeomanson, D; Picarsic, J; Allen, C; Bigley, V; Collin, M. Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis. Blood Advances. 2023; 7:2171-2176.\n\nMinneci, PC; Bergus, KC; Lutz, C; Aldrink, J; Bence, C; Breech, L; Dillon, PA; Downard, C; Ehrlich, PF; Fallat, M; Sato, TT; St Peter, SD; Cooper, J; Deans, K. Reducing Unnecessary Oophorectomies for Benign Ovarian Neoplasms in Pediatric Patients. Journal of the American Medical Association. 2023; 330:1247-1254.\n\nMochizuki, A; Partap, S. Pediatric Embryonal Tumors. In: Mrugala MM; Gatson NTN; Kurz SC; Nevel KS; Clarke JL, Ed. Neuro-Oncology Compendium for the Boards and Clinical Practice. : Oxford University Press (OUP); Oxford University Press (OUP); 2023.\n\nModur, V; Muhammad, B; Yang, JQ; Zheng, Y; Komurov, K; Guo, F. Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. Cell Reports. 2023; 42:112364.\n\nMontiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; Wood, EH. Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Pediatric Blood and Cancer. 2023; 70:e30429.\n\nMorrison, A; Pressey, J; Roth, LP; Tulchinskaya, V; Strieich-TIlles, T. 34. Atypical Presentation of Granulosa Cell Tumor in an Adolescent: A Case Report. Journal of Pediatric and Adolescent Gynecology. 2023; 36:187.\n\nMorrison, A; Pressey, JG; VandenHeuvel, K; Streich-Tilles, T. Atypical Presentation of Granulosa Cell Tumor in an Adolescent: A Case Report. Journal of Pediatric and Adolescent Gynecology. 2023; 36:553-555.\n\nMoscato, EL; Fisher, AP; Pillay-Smiley, N; Salloum, R; Wade, SL. Caregivers matter: Neurological vulnerability for pediatric brain tumor survivors. 2023; 10:418-428.\n\nMujahid, H; Gupta, A; Hammill, A; Towe, CT; McCormack, FX. Complex Thoracic Lymphatic Disorders of Adults. Orphan Lung Diseases. : Springer Nature; Springer Nature; 2023.\n\nMullins, E; Larcey, R; Meisman, A; Mullins, T. PB1495 Comfort and Experiences Providing Care to Transgender Youth Among Hematologists in the Midwestern United States. Research and Practice in Thrombosis and Haemostasis. 2023; 7:101848.\n\nMullins, ES; Larcey, R; Meisman, A; Mullins, TL K. Attitudes of Hematologists in the Midwestern United States Toward Evaluating and Managing Thrombosis Risk in Transgender Youth Starting Gender Affirming Hormone Therapy. Blood. 2023; 142:3685.\n\nMurphy, AJ; Cheng, C; Williams, J; Shaw, TI; Pinto, EM; Dieseldorff-Jones, K; Brzezinski, J; Renfro, LA; Tornwall, B; Huff, V; Zambetti, GP; Wang, Z; Davidoff, AM; Chen, X. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q. Nature Communications. 2023; 14:8006.\n\nMuto, T; Walker, CS; Agarwal, P; Vick, E; Sampson, A; Choi, K; Niederkorn, M; Ishikawa, C; Hueneman, K; Varney, M; Starczynowski, DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica: the hematology journal. 2023; 108:2715-2729.\n\nNa, B; Wang, AC; Watterson, CT; Martinez-Agosto, J; Saitta, S; Dutra-Clarke, M; Bhansali, F; Pineles, SL; Chang, VY; Shah, VS; de Blank, P. An unusual presentation of bilateral optic pathway glioma in Crouzon Syndrome. Pediatric Hematology-Oncology (Informa). 2023; 40:800-806.\n\nNa, Y; Hall, A; Yu, Y; Hu, L; Choi, K; Burgard, JA; Szabo, S; Huang, G; Ratner, N; Wu, J. Runx1/3-driven adaptive endoplasmic reticulum stress pathways contribute to neurofibromagenesis. Oncogene: Including Oncogene Reviews. 2023; 42:1038-1047.\n\nNamazzi, R; Opoka, R; Conroy, AL; Datta, D; Tagoola, A; Bond, C; Goings, MJ; Ryu, MS; Cusick, SE; Krebs, NF; Jang, JH; Tu, W; Ware, RE; John, CC. Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Advances. 2023; 7:3023-3031.\n\nNeidemire-Colley, LM; Khanal, S; Braunreiter, KM; Snyder, KJ; Gao, Y; Kalyan, S; Kararoud, MN; Duszynsk, M; Chi, M; Malik, P; Choe, H; Garzon, R; Ranganathan, P. CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease. Journal of immunology (Baltimore, Md. : 1950). 2023; 210:173.21.\n\nNguyen, HT; Tang, W; Webster, AL H; Whiteaker, JR; Chandler, CM; Errazquin, R; Roohollahi, K; Fritzke, M; Hoskins, EE; Jonlin, E; Garcia-Escudero, R; Wells, SI; Smogorzewska, A; Monnat, RJ. Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource. International Journal of Cancer. 2023; 153:183-196.\n\nO'Brien, MM; McNeer, JL; Rheingold, SR; Devidas, M; Chen, Z; Bhojwani, D; Ramsey, LB; Agrawal, A; Wood, BL; Suh, E; Burke, M; Salzer, WL; Raetz, EA; Loh, ML. A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732. Journal of Clinical Oncology. 2023; 41:10016.\n\nOdegard, E; Meeds, H; Kleiboeker, S; Ziady, A; Sabulski, DA; Jodele, S; Seif, AE; Davies, SM; Laskin, B; Blackard, JT. 429 BK Polyomavirus after Pediatric Hematopoietic Stem Cell Transplantation. Transplantation and cellular therapy. 2023; 29:s324-s325.\n\nOdegard, EA; Meeds, HL; Kleiboeker, SB; Ziady, A; Sabulski, A; Jodele, S; Seif, AE; Davies, SM; Laskin, BL; Blackard, JT. BK Polyomavirus Diversity After Hematopoietic Stem Cell Transplantation. Journal of Infectious Diseases. 2023; 228:1208-1218.\n\nOla, R; Hessels, J; Hammill, A; Friday, C; Clancy, M; Al-Samkari, H; Meadows, S; Iyer, V; Akhurst, R. Executive summary of the 14th HHT international scientific conference. Angiogenesis. 2023; 26:27-37.\n\nOlsen, E; King, J; Pollock, JR; Squires, M; Meremikwu, R; Walton, D; Davies, SM; Badia, P. Hammer Toe Correction with Proximal Interphalangeal Joint Arthrodesis. JBJS Essential Surgical Techniques. 2023; 13:e21.00046.\n\nOlupot-Olupot, P; Tomlinson, G; Williams, TN; Tshilolo, L; Santos, B; Smart, LR; McElhinney, K; Howard, TA; Aygun, B; Stuber, SE; Lane, A; Latham, TS; Ware, RE. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023; 141:1402-1410.\n\nO'Neill, AF; Meyers, RL; Katzenstein, HM; Geller, JI; Tiao, GM; López-Terrada, D; Malogolowkin, M. Children's Oncology Group's 2023 blueprint for research: Liver tumors. Pediatric Blood and Cancer. 2023; 70 Suppl 6:e30576.\n\nO'Toole, D; Groth, D; Wright, H; Bonilla, FA; Cunningham-Rundles, C; Sullivan, KE; Ochs, HD; Marsh, RA; Feuille, E; Fuleihan, RL. Outcomes among racial and ethnic minority groups with X-linked agammaglobulinemia from the USIDNET registry. Journal of Allergy and Clinical Immunology: In Practice. 2023; 11:1945-1946.\n\nOttesen, EW; Singh, NN; Luo, D; Kaas, B; Gillette, BJ; Seo, J; Jorgensen, HJ; Singh, RN. Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Research. 2023; 51:5948-5980.\n\nPai, AL; Deckelman, A; Leone, M; Drake, S; Bills, S; Klink, G; Joffe, N; Grimley, MS; Dandoy, DC E. 194 Adherence Barriers in Pediatric Hematopoietic Stem Cell Transplant in an Outpatient Setting. Transplantation and cellular therapy. 2023; 29:s153-s154.\n\nPalmisani, E; Miano, M; Grossi, A; Lanciotti, M; Lupia, M; Terranova, P; Ceccherini, I; Montanari, E; Calvillo, M; Pierri, F; Crescenzio, N; Bleesing, J; Dufour, C; Fioredda, F. Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?. HemaSphere. 2023; 7:e845.\n\nPerales, M; Chemaly, DR F; Dandoy, DC E; He, N; Martens, MJ; Riches, M; Szabolcs, P. 409 Delayed CD4+ T Cell Recovery after Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Overall Survival in Adult but Not Pediatric Recipients. Transplantation and cellular therapy. 2023; 29:s309.\n\nPeyvandi, F; Tarango, C; Simpson, M; Albisetti, M; Álvarez-Roman, MT; Chan, AK C; Curtin, J; Bystrická, L; Santagostino, E; Gresko, E; Gunawardena, S; Vage, C; Wong, N. Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A. Blood. 2023; 142:506.\n\nPhillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. 2023; 2:1151744.\n\nPiel, FB; Rees, DC; DeBaun, MR; Nnodu, O; Ranque, B; Thompson, AA; Ware, RE; Abboud, MR; Abraham, A; Ambrose, EE; Sung, L; Tshilolo, L; Wilkie, DJ; Ohene-Frempong, K. Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. 2023; 10:e633-e686.\n\nPillay-Smiley, N; Fletcher, JS; de Blank, P; Ratner, N. Shedding New Light: Novel Therapies for Common Disorders in Children with Neurofibromatosis Type I. Pediatric Clinics of North America. 2023; 70:937-950.\n\nPillay-Smiley, N; Leach, J; Lane, A; Hummel, T; Fangusaro, J; de Blank, P. Evaluating Focal Areas of Signal Intensity (FASI) in Children with Neurofibromatosis Type-1 (NF1) Treated with Selumetinib on Pediatric Brain Tumor Consortium (PBTC)-029B. Cancers. 2023; 15:2109.\n\nPradhan, A; Che, L; Ustiyan, V; Reza, AA; Pek, NM; Zhang, Y; Alber, AB; Kalin, TR; Wambach, JA; Gu, M; Kotton, DN; Siefert, ME; Ziady, AG; Kalin, TV; Kalinichenko, VV. Novel FOXF1-Stabilizing Compound TanFe Stimulates Lung Angiogenesis in Alveolar Capillary Dysplasia. American Journal of Respiratory and Critical Care Medicine. 2023; 207:1042-1054.\n\nQuinn, CT. Hydroxyurea: how much is enough?. Blood. 2023; 141:813-814.\n\nQuinn, CT; Wiedmann, RT; Jarovsky, D; Lopez-Medina, E; Rodriguez, HM; Papa, M; Boggio, G; Shou, Q; Dagan, R; Richmond, P; Tamms, G; Lupinacci, R; Musey, L; Bickham, K. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study. Blood Advances. 2023; 7:414-421.\n\nRadulovic, I; Schündeln, MM; Müller, L; Ptok, J; Honisch, E; Niederacher, D; Wiek, C; Scheckenbach, K; Leblanc, T; Larcher, L; Soulier, J; Reinhardt, D; Schaal, H; Andreassen, PR; Hanenberg, H. A novel cancer risk prediction score for the natural course of FA patients with biallelic BRCA2/FANCD1 mutations. Human Molecular Genetics. 2023; 32:1836-1849.\n\nRaetz, EA; Teachey, DT; Minard, C; Liu, X; Norris, RE; Denic, KZ; Reid, J; Evensen, NA; Gore, L; Fox, E; Loh, ML; Weigel, BJ; Carroll, WL. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Pediatric Blood and Cancer. 2023; 70:e30609.\n\nRamanathan, M; Kim, S; He, N; Chen, M; Hematti, P; Abid, MB; Rotz, SJ; Williams, KM; Lazarus, HM; Wirk, B; Chemaly, RF; Dandoy, CE; Riches, M; Ustun, C. The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transplantation. 2023; 58:360-366.\n\nRamsey, LB; Prows, CA; Chidambaran, V; Sadhasivam, S; Quinn, CT; Teusink-Cross, A; Tang Girdwood, S; Dawson, DB; Vinks, AA; Glauser, TA. Implementation of CYP2D6-guided opioid therapy at Cincinnati Children's Hospital Medical Center. American Journal of Health-System Pharmacy. 2023; 80:852-859.\n\nRankine-Mullings, A; Keenan, R; Chakravorty, S; Inusa, B; Telfer, P; Velangi, M; Ware, RE; Moss, JJ; Lloyd, AL; Edwards, S; Mulla, H. Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Advances. 2023; 7:4319-4322.\n\nRankine-Mullings, AE; Soares, D; Aldred, K; Chang-Lopez, S; Wisdom-Phipps, ME; Schultz, W; Latham, TS; Stuber, SE; Jackson, P; Ware, RE; Reid, ME. Hydroxyurea Improves Intelligence Quotient Scores in Children with Sickle Cell Anemia and Elevated Transcranial Doppler Velocity. Blood. 2023; 142:797.\n\nRatner, N; Hu, L; Pundavela, J; Epstein, JA. Abstract IA17: Use of RAS isoforms in nerve tumors. Molecular cancer research : MCR. 2023; 21:ia17.\n\nReed, HD; Do, H; Weller, E; Farrar, JE; Gamper, C; Lau, BW; Pommert, L; Atkinson, I; Joos, M; Loveless, S; Steltz, S; Myers, K; Shimamura, A. Lymphoid Malignancies in Shwachman-Diamond Syndrome: Incidence, Clinical Features, and Outcomes from the North American SDS Registry. Blood. 2023; 142:5662.\n\nRineer, S; Walsh, PS; Smart, LR; Harun, N; Schnadower, D; Lipshaw, MJ. Risk of Bacteremia in Febrile Children and Young Adults With Sickle Cell Disease in a Multicenter Emergency Department Cohort. JAMA Network Open. 2023; 6:e2318904.\n\nRisinger, M; Kim, PS; Rodriguez, RX; Narvaez Rivas, M; Setchell, KD R; Zhang, W; Kalfa, TA. Hemolytic anemia and macrothrombocytopenia: A lipid problem?. American Journal of Hematology. 2023; 98:1335-1340.\n\nRobinson, TM; Bowman, RL; Persaud, S; Liu, Y; Neigenfind, R; Gao, Q; Zhang, J; Sun, X; Miles, LA; Cai, SF; Dogan, A; Roshal, M; Levine, RL; Xiao, W. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Science Advances. 2023; 9:eadg0488.\n\nRoehrig, A; Indelicato, DJ; Paulino, AC; Ermoian, R; Hartsell, W; Perentesis, J; Hill-Kayser, C; Lee, JY; Laack, NN; Mangona, V; Gallotto, S; Bajaj, BV M; Aridgides, PD; Yock, TI. Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR). Journal of Neuro-Oncology. 2023; 162:353-362.\n\nRomano, L; Ntoumaziou, A; Gardner, JC; Stewart, M; Paulson, R; Salomonis, N; Blanc, L; Seu, K; Kalfa, TA. Leveraging Transcriptomic Data to Study Erythromyeloblastic Island (EMBI) Macrophages: Using Spic-GFP As a Marker for Embi Macrophages. Blood. 2023; 142:3832.\n\nRomano, L; Seu, KG; Blanc, L; Kalfa, TA. Crosstalk between terminal erythropoiesis and granulopoiesis within their common niche: the erythromyeloblastic island. Current Opinion in Hematology. 2023; 30:99-105.\n\nRoot, MC; Koo, J; Collins, G; Penumarthy, NL; Hermiston, M; Bogetz, JF. Allowing Relationships to Unfold: Consult Reason and Topics Discussed in Initial and Subsequent Palliative Care Visits Among Children Who Died From Relapsed/Refractory Cancer. 2023; 40:170-177.\n\nRosenbaum, JS; Kolt, AS; Hoyt, SB; Hayes, GM; Soldo, BL; Thomas, CJ; Starczynowski, DT. Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients. Blood. 2023; 142:4152.\n\nRotz, SJ; Heim, M; Kim, S; Gennery, A; Georges, GE; Myers, K; Broglie, L; Eissa, H. Hematopoietic Stem Cell Transplantation for Fanconi Anemia: Outcome and Prognostic Factors for Survival and Subsequent Neoplasms. Blood. 2023; 142:948.\n\nRubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and cellular therapy. 2023; 29:311.e1-311.e7.\n\nSabulski, A; Abdullah, S; Luebbering, N; Aunins, B; Castillo, C; Lake, K; Duell, A; Strecker, L; Langenberg, L; Broomhead, W; Dandoy, CE; Laskin, BL; Jodele, S; Davies, SM. Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma. Haematologica: the hematology journal. 2023; 108:3449-3453.\n\nSabulski, A; Jodele, S. Peering into the darkness of drug-induced thrombotic microangiopathy: complement, are you in there?. Journal of Gastrointestinal Oncology. 2023; 14:468-471.\n\nSabulski, DA; Myers, K; Davies, SM; Jodele, S. 406 All Eyes on Interferon in Graft Failure after Hematopoietic Stem Cell Transplant. Transplantation and cellular therapy. 2023; 29:s306-s307.\n\nSabulski, DA; Segev, N; Hornung, L; Wasserman, H; Myers, K; Howell, JC. 24 Longitudinal Risk of Bone Disease in a Diverse Pediatric Population Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Transplantation and cellular therapy. 2023; 29:s20-s21.\n\nSabulski, DA; Siefert, ME; Skala, E; Abdullah, S; Luebbering, N; Myers, K; Odegard, E; Blackard, JT; Seif, AE; Jodele, S; Davies, SM; Laskin, B; Ziady, A. 77 Proteomic Analyses Reveal Molecular Connections That Support the Clinical Association of Cystitis with Thrombotic Microangiopathy in Pediatric Transplant Recipients. Transplantation and cellular therapy. 2023; 29:s64-s65.\n\nSadaf, A; Dong, M; Korpik, J; Pfeiffer, A; Kalfa, TA; Latham, TS; Vinks, AA; Ware, RE; Quinn, CT. Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis. Blood. 2023; 142:1145.\n\nSafeukui, I; Ware, RE; Mohandas, N; Haldar, K. Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Advances. 2023; 7:5970-5981.\n\nSalloum, R; Huang, J; Stewart, CF; Fuller, C; Smolarek, T; Lenzen, A; Waanders, AJ; Baxter, P; Lindsay, H; Robison, N; Fangusaro, J; Onar-Thomas, A; Fouladi, M; Dunkel, IJ. TRLS-11. A PHASE 1 STUDY OF SAVOLITINIB IN RECURRENT, PROGRESSIVE, OR REFRACTORY MEDULLOBLASTOMA, HIGH-GRADE GLIOMA, DIFFUSE INTRINSIC PONTINE GLIOMA, AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS HARBORING MET ABERRATIONS: A PEDIATRIC BRAIN TUMOR CONSORTIUM TRIAL. Neuro-Oncology. 2023; 25:i81.\n\nSchoettler, ML; Carreras, E; Cho, B; Dandoy, CE; Ho, VT; Jodele, S; Moissev, I; Sanchez-Ortega, I; Srivastava, A; Atsuta, Y; Shaw, BE; Sureda, A; Soiffer, R; Vasu, S. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplantation and cellular therapy. 2023; 29:151-163.\n\nSchoettler, ML; Carreras, ME; Cho, B; Dandoy, DC E; Ho, DV T; Jodele, S; Moiseev, I; Sanchez-Ortega, I; Srivastava, A; Atsuta, Y; Soiffer, RJ; Sureda, A; Williams, A; Vasu, S. 162 Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplant Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation (EBMT), American Society for Transplantation and Cellular Therapy (ASTCT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). Transplantation and cellular therapy. 2023; 29:s130-s131.\n\nSchoettler, ML; Dandoy, CE; Harris, A; Chan, M; Tarquinio, KM; Jodele, S; Qayed, M; Watkins, B; Kamat, P; Petrillo, T; Dvorak, CC; Westbrook, A; Zinter, MS; Williams, KM. Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality. Frontiers in Oncology. 2023; 13:1232621.\n\nSchoettler, ML; Lehmann, LE; Kao, P; Chen, N; Jodele, S; London, WB; Duncan, CN; Dandoy, DC E. 161 Healthcare Utilization in Children with Transplant Associated Thrombotic Microangiopathy and the Impact of Eculizumab Therapy. Transplantation and cellular therapy. 2023; 29:s129-s130.\n\nSchrenk, S; Bischoff, LJ; Goines, J; Cai, Y; Vemaraju, S; Odaka, Y; Good, SR; Palumbo, JS; Szabo, S; Reynaud, D; Van Raamsdonk, CD; Lang, RA; Boscolo, E. MEK inhibition reduced vascular tumor growth and coagulopathy in a mouse model with hyperactive GNAQ. Nature Communications. 2023; 14:1929.\n\nSchuster, JE; Hamdan, L; Dulek, DE; Kitko, CL; Batarseh, E; Haddadin, Z; Stewart, LS; Stahl, A; Potter, M; Rahman, H; Munoz, FM; Danziger-Isakov, L; Spieker, AJ; Halasa, N. Influenza Vaccine in Pediatric Recipients of Hematopoietic-Cell Transplants. The New England journal of medicine. 2023; 388:374-376.\n\nSchwede, M; Jahn, K; Miles, LA; Bowman, RL; Kuipers, J; Robinson, TM; Ediriwickrema, A; Gentles, AJ; Levine, R; Beerenwinkel, N; Takahashi, K; Majeti, R. Abstract A49: Characterizing the order of mutation acquisition in acute myeloid leukemia using large-scale single-cell sequencing. 2023; 4:a49.\n\nSekyonda, Z; Kityo, C; Elgammal, Y; Kalfa, TA; Akkus, O; Gurkan, UA. Rapid Assessment of Hemoglobin-Oxygen Dissociation. Blood. 2023; 142:2270.\n\nShakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; de Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Arthritis and Rheumatology. 2023; 75:1714-1732.\n\nShakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; Goldbach-Mansky, R; De Benedetti, F; Marsh, RA; Canna, SW. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Annals of the Rheumatic Diseases. 2023; 82:1271-1285.\n\nSharma, B; Francisco, B; Rosenfeldt, L; Cantrell, R; Revenko, A; Monia, B; Flick, M; Palumbo, J. PB0708 The Tissue Factor/Thrombin Axis Limits Spontaneous Lymphatic Metastasis in Mice. Research and Practice in Thrombosis and Haemostasis. 2023; 7:101305.\n\nSharma, S; Ursery, LT; Bharathi, V; Miles, SD; Williams, WA; Elzawam, AZ; Schmedes, CM; Egnatz, GJ; Fernandez, JA; Palumbo, JS; Griffin, JH; Mackman, N; Antoniak, S. APC-PAR1-R46 signaling limits CXCL1 expression during poly IC-induced airway inflammation in mice. Journal of Thrombosis and Haemostasis. 2023; 21:3279-3282.\n\nShim, YJ; Sharma, BK; Hisada, Y; Mackman, N; Palumbo, JS; Diaz-Montero, C; Khorana, AA; McCrae, KR. Immune Checkpoint Blockade Promotes Thrombosis Via T-Cell and Neutrophil Activation, and Tumor-Cell Associated Tissue Factor (TF) in a Murine Model of Colorectal Cancer. Blood. 2023; 142:1192.\n\nShook, LM; Lang, A; King, AA; Smith-Whitley, K; Thompson, AA; Barriteau, CM; Schwartz, L; Mosely, C; Oke, E; Jallow, F; Crosby, LE. SCD and COVID-19 Vaccines: What Do Pediatric Patients Want to Know?. Blood. 2023; 142:7199.\n\nShukla, S; Saha, T; Rama, N; Acharya, A; Le, T; Bian, F; Donovan, J; Tan, LA; Vatner, R; Kalinichenko, V; Mascia, A; Perentesis, JP; Kalin, TV. Ultra-high dose-rate proton FLASH improves tumor control. Radiotherapy and Oncology. 2023; 186:109741.\n\nSidonio,, RF; Bryant, PC; Di Paola, J; Hale, S; Heiman, M; Horowitz, GS; Humphrey, C; Jaffray, J; Joyner, LC; Kasthuri, R; Trapane, P; Wang, M; Waters, B; Flood, VH. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders. Expert Review of Hematology. 2023; 16:39-54.\n\nSingh, AK; Prasad, P; Cancelas, JA. Mesenchymal stromal cells, metabolism, and mitochondrial transfer in bone marrow normal and malignant hematopoiesis. Frontiers in Cell and Developmental Biology. 2023; 11:1325291.\n\nSirhan, Z; Sells, BE; Fleming, J; Manring, HR; Graham, RT; McElroy, JP; Haque, SJ; Boué, DR; Becker, AP; Bell, EH; Finlay, J; Chakravarti, A. BIOL-05. IDENTIFICATION AND VALIDATION OF PA2G4 AS A POTENTIAL THERAPEUTIC TARGET IN PEDIATRIC DIFFUSE GLIOMAS. Neuro-Oncology. 2023; 25:i6.\n\nSmart, LR; Ambrose, EE; Balyorugulu, G; Songoro, P; Shabani, I; Komba, P; Charles, M; Howard, TA; McElhinney, KE; O'Hara, SM; Lane, A; Latham, TS; Makubi, AN; Ware, RE. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. Acta Haematologica. 2023; 146:95-105.\n\nSmart, LR; Charles, M; McElhinney, KE; Dong, M; Power-Hays, A; Howard, T; Vinks, AA; Ambrose, EE; Ware, RE. Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Frontiers in Molecular Biosciences. 2023; 10:1130206.\n\nSmart, LR; Segbefia, CI; Latham, TS; Stuber, SE; Amissah-Arthur, KN; Dzefi-Tettey, K; Lane, AC; Dei-Adomakoh, YA; Ware, RE. Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. Trials. 2023; 24:603.\n\nSomers, KM; Tabbouche, RB; Bondoc, A; Towbin, AJ; Ranganathan, S; Tiao, G; Geller, JI. Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience. Cancers. 2023; 15:3921.\n\nSoni, UK; Wang, Y; Pandey, RN; Roberts, R; Pressey, JG; Hegde, RS. Molecularly Defined Subsets of Ewing Sarcoma Tumors Differ in Their Responses to IGF1R and WEE1 Inhibition. Clinical Cancer Research. 2023; 29:458-471.\n\nStahl, M; Abdel-Wahab, O; Wei, AH; Savona, MR; Xu, ML; Xie, Z; Taylor, J; Starczynowski, D; Sanz, GF; Sallman, DA; Steensma, DP; Sekeres, MA; Buckstein, RJ; Zeidan, AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances. 2023; 7:2709-2714.\n\nStahl, M; Bewersdorf, JP; Xie, Z; Porta, MG D; Komrokji, R; Xu, ML; Abdel-Wahab, O; Taylor, J; Steensma, DP; Starczynowski, DT; Wei, AH; Santini, V; Savona, MR; Zeidan, AM. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Reviews. 2023; 62:101128.\n\nStahl, M; Derkach, A; Farnoud, N; Bewersdorf, JP; Robinson, T; Famulare, C; Cho, C; Devlin, S; Menghrajani, K; Patel, MA; Papaemmanuil, E; Tallman, MS; Roshal, M; Goldberg, AD. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal of Hematology. 2023; 98:79-89.\n\nStarczynowski, DT. 1031 – FROM PRE-LEUKEMIC STATES TO MALIGNANT TRANSFORMATION: UNRAVELING THE ROLE OF DYSREGULATED INNATE IMMUNE SIGNALING AND INFLAMMATION IN MYELOID MALIGNANCIES. Experimental Hematology. 2023; 124:s35.\n\nStefanski, HE; Eaton, A; Baggott, C; Rossoff, J; Verneris, MR; Prabhu, S; Pacenta, HL; Phillips, CL; Talano, J; Moskop, A; Curran, KJ; Mackall, CL; Laetsch, TW; Schultz, LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Advances. 2023; 7:541-548.\n\nStrong, H; Hood, AM; Johnson, Y; Hackworth, R; Reed-Shackelford, M; Ramaswamy, R; Varughese, T; Quinn, CT; Crosby, LE. Using the consolidated framework for implementation research to identify recruitment barriers and targeted strategies for a shared decision-making randomized clinical trial in pediatric sickle cell disease. Clinical Trials. 2023; 20:211-222.\n\nTakahashi, T; Al-Kofahi, M; Jaber, M; Bratrude, B; Betz, K; Suessmuth, Y; Yu, A; Neuberg, DS; Choi, SW; Davis, J; Watkins, B; Langston, A; Qayed, M; Kean, LS. Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events. Blood. 2023; 142:700-710.\n\nTalley, MJ; Nardini, D; Ehrman, LA; Lu, QR; Waclaw, RR. Distinct requirements for Tcf3 and Tcf12 during oligodendrocyte development in the mouse telencephalon. Neural Development. 2023; 18:5.\n\nTamang, HK; Stringham, EN; Tourdot, BE. Platelet Functional Testing Via High-Throughput Microtiter Plate-Based Assays. 2023; 3:e668.\n\nTarango, C; Quinn, CT; Augsburger, B; Lucky, AW. Iron status and burden of anemia in children with recessive dystrophic epidermolysis bullosa. Pediatric Dermatology. 2023; 40:288-293.\n\nTaylor, JM; Hammill, AM. The Role of Hereditary Hemorrhagic Telangiectasia in Neurologic Practice. Neurology. 2023; 100:1077-1078.\n\nTaylor, ZL; Miller, TP; Poweleit, EA; DeGroote, NP; Pommert, L; Awoniyi, O; Board, SG; Ugboh, N; Joshi, V; Ambrosino, N; Schafer, ES; O'Brien, MM; Castellino, SM; Ramsey, LB. Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org. Clinical and Translational Science. 2023; 16:2130-2143.\n\nTeigen, D; Opoka, RO; Kasirye, P; Nabaggala, C; Hume, HA; Blomberg, B; John, CC; Ware, RE; Robberstad, B. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. Pharmacoeconomics Italian Research Articles. 2023; 41:1603-1615.\n\nTeng, JM C; Hammill, A; Martini, J; Treat, J. Sirolimus in the Treatment of Microcystic Lymphatic Malformations: A Systematic Review. Lymphatic Research and Biology. 2023; 21:101-110.\n\nTeoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; Schulert, GS. Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. The Pediatric Infectious Disease Journal. 2023; 42:119-121.\n\nTeoh, Z; Simpson, BN; Howard, T; McElhinney, K; Ware, R; Mena, R; Schlaudecker, EP. Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. The Pediatric Infectious Disease Journal. 2023; 42:965-968.\n\nThakar, MS; Logan, BR; Puck, JM; Dunn, EA; Buckley, RH; Cowan, MJ; O'Reilly, RJ; Kapoor, N; Satter, LF; Pai, SY; Griffith, LM; Haddad, E; Dvorak, CC; Notarangelo, LD. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. The Lancet. 2023; 402:129-140.\n\nThant, M; Cancelas, J; Kaplan, A. The enhanced direct antiglobulin test in current practice has a limited impact on management of adult patients. Transfusion and Apheresis Science. 2023; 62:103768.\n\nThompson, M; Sakabe, M; Verba, M; Hao, J; Meadows, SM; Lu, QR; Xin, M. PRDM16 regulates arterial development and vascular integrity. Frontiers in Physiology. 2023; 14:1165379.\n\nThompson, M; Sakabe, M; Xin, M. Abstract 664: Essential Roles Of Prdm16 In Repression Of Venous Marker In The Artery. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023; 43.\n\nTodd, K; Luchtman-Jones, L; Blackmore, A; Hennessey, C; McGrady, ME. Barriers to medication adherence in children, adolescents, and young adults prescribed anticoagulation. Pediatric Blood and Cancer. 2023; 70:e30076.\n\nTorous, DK; Avlasevich, S; Bemis, JC; Howard, T; Ware, RE; Fung, C; Chen, Y; Sahsrabudhe, D; MacGregor, JT; Dertinger, SD. Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environmental and Molecular Mutagenesis. 2023; 64:167-175.\n\nTreichel, S; Filippi, MD. Linking cell cycle to hematopoietic stem cell fate decisions. Frontiers in Cell and Developmental Biology. 2023; 11:1231735.\n\nTrout, AT; Norris, RE; de Blank, PM K; Backus, LR; Towbin, AJ; Nash, JM. Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Pediatric Blood and Cancer. 2023; 70:e30362.\n\nTuff-Gordon, E; Faughnan, ME; Kim, H; Lawton, MT; Vozoris, NT; Brain Vascular Malformation Consortium HHT Investi, ; Brain Vascular Malformation Consortium HHT Investi, . An analysis of sex differences in pulmonary arteriovenous malformation presentation, complications and management in a large, multinational registry of patients with hereditary haemorrhagic telangiectasia. ERJ Open Research. 2023; 9:751-2022.\n\nTweddell, JS; Kharnaf, M; Zafar, F; Riggs, KW; Reagor, JA; Monia, BP; Revenko, A; Leino, DG; Owens, AP; Martin, JK; Gourley, B; Rosenfeldt, L; Palumbo, JS. Targeting the contact system in a rabbit model of extracorporeal membrane oxygenation. Blood Advances. 2023; 7:1404-1417.\n\nUible, EE; Choi, K; Hueneman, K; Bolanos, LC; Greis, K; Starczynowski, DT. The Zymogen Form of Caspase-1 Is Required to Fine Tune Excessive Cell-Intrinsic Inflammation in Acute Myeloid Leukemia. Blood. 2023; 142:1391.\n\nVerma, R; Chen, X; Xin, D; Luo, Z; Ogurek, S; Xin, M; Rao, R; Berry, K; Lu, QR. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities. Cancer Research. 2023; 83:890-905.\n\nVick, EJ; Bennett, J; Cochran, AE; Hueneman, K; Bolanos, LC; Zhang, X; McKnight, C; Ceribelli, M; Klumpp-Thomas, C; Choi, K; Greis, K; Thomas, CJ; Starczynowski, DT. Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies. Blood. 2023; 142:45.\n\nWagner, ML; Ammann, A; Piraino, G; Wolfe, V; O'Connor, M; Lahni, P; Ziady, A; Zingarelli, B. PROTECTIVE EFFECTS OF HUMANIN-G IN HEMORRHAGIC SHOCK IN FEMALE MICE VIA AMPKα1-INDEPENDENT MECHANISMS. Shock. 2023; 60:64-74.\n\nWalulik, S; Dean, S; Vick, EJ; Zhu, X; Wunderlich, M; Chou, C; Choi, K; Grimes, HL; Starczynowski, DT; Miles, LA; Volk, A. The Mechanism of Therapy Resistance By Lineage Plasticity in AML and How to Overcome It. Blood. 2023; 142:1410.\n\nWang, C; Tu, Z; Cai, X; Wang, W; Davis, AK; Nattamai, K; Paranjpe, A; Dexheimer, P; Wu, J; Huang, FL; Geiger, H; Huang, G; Zheng, Y. A critical role of RUNX1 in governing megakaryocyte-primed hematopoietic stem cell differentiation. Blood Advances. 2023; 7:2590-2605.\n\nWang, C; Zheng, Y; Fan, C; Tu, Z; Cai, X; Wu, J; Huang, G. Conserved and Unique Regulatory Mechanisms of RUNX1 in Hematopoietic Stem/Progenitor Cell Subpopulations in Both Normal Hematopoiesis and FPD/AML Development. Blood. 2023; 142:1314.\n\nWang, D; Myers, KC; Bresnick, EH; Verbsky, J; Thakar, M; Malarkannan, S. GATA2-TGF-b1 axis regulates human NK cell development. Journal of immunology (Baltimore, Md. : 1950). 2023; 210:162.02.\n\nWang, F; Wang, W; Gu, S; Qi, D; Smith, NA; Peng, W; Dong, W; Yuan, J; Zhao, B; Mao, Y; Shapiro, LA; Yi, SS; Wu, E; Huang, JH. Distinct astrocytic modulatory roles in sensory transmission during sleep, wakefulness, and arousal states in freely moving mice. Nature Communications. 2023; 14:2186.\n\nWang, YM; Abdullah, S; Luebbering, N; Langenberg, L; Duell, A; Lake, K; Lane, A; Hils, B; Silva, OV; Trapp, M; Haslam, DB; Faubion, WA; Davies, SM; Khandelwal, P. Intestinal permeability in patients undergoing stem cell transplantation correlates with systemic acute phase responses and dysbiosis. Blood Advances. 2023; 7:5137-5151.\n\nWang, YM; Dandoy, CE; Smith, DF; Hogenesch, JB. Go to bed!: Sleep as a risk factor for adolescent hypertension. Progress in Pediatric Cardiology. 2023; 68:101613.\n\nWang, YM; Taggart, CB; Huber, J; Davies, SM; Smith, DF; Hogenesch, JB; Dandoy, DC E. 167 Earlier Oral Intake in Pediatric Stem Cell Transplant Patients Receiving Time-Restricted Feeding: A Prospective, Randomized Trial. Transplantation and cellular therapy. 2023; 29:s135.\n\nWang, YZ M; Loveless, M; Miller, E; Nelson, AS; Mehta, PA; Davies, SM; Myers, KC. Phenotypes of adults with Fanconi anaemia. British Journal of Haematology. 2023; 201:133-139.\n\nWang, YZ M; Taggart, CB; Huber, JF; Davies, SM; Smith, DF; Hogenesch, JB; Dandoy, CE. Daytime-restricted parenteral feeding is associated with earlier oral intake in children following stem cell transplant. The Journal of Clinical Investigation. 2023; 133:e167275.\n\nWare, J; Mcelhinney, K; Latham, T; Lane, A; Dienger-Stambaugh, K; Hildeman, D; Spearman, P; Ware, RE. Sustained and Boosted Antibody Responses in Breast Milk After Maternal SARS-CoV-2 Vaccination. Breastfeeding Medicine. 2023; 18:612-620.\n\nWilcher, KE; Page, ER H; Privette Vinnedge, LM. The impact of the chromatin binding DEK protein in hematopoiesis and acute myeloid leukemia. Experimental Hematology. 2023; 123:18-27.\n\nWilliams, M; Sugimoto, C; Regan, S; Pitzer, E; Fritz, A; Sertorio, M; Mascia, A; Vatner, R; Perentesis, J; Vorhees, C. Cognitive and behavioral effects of whole brain conventional or high dose rate (FLASH) proton irradiation in a neonatal Sprague Dawley rat model. Neurotoxicology and Teratology. 2023; 98:107276.\n\nWilson, HP; Betensky, M; Miller, A; Amankwah, EK; Mosha, M; Fargo, JH; Mahajerin, A; Thornburg, C; Tarango, C; Acharya, S; Male, C; Narang, S; Schulman, S; Goldenberg, N. Use and Outcomes of Secondary Anticoagulation in Patients <21 Years Old Following Completion of a Primary Course of Anticoagulation for Treatment of Acute Provoked VTE: Findings from the Multinational Kids-DOTT Trial. Blood. 2023; 142:1275.\n\nWong, CI; Vannatta, K; Gilleland Marchak, J; Quade, EV; Rodgers, IM; Reid, CM; Dandoy, CE; Billett, AL; Miller, TP; Vaughn, S; Daraiseh, NM; Liu, S; Carle, AC; Walsh, KE. Preventable harm because of outpatient medication errors among children with leukemia and lymphoma: A multisite longitudinal assessment. Cancer. 2023; 129:1064-1074.\n\nWyatt, KD; Noyd, DH; Wood, NM; Phillips, CA; Miller, TP; Rubin, EM; Winestone, LE; Waanders, AJ; Perentesis, JP; Aplenc, R. Data standards in pediatric oncology: Past, present, and future. Pediatric Blood and Cancer. 2023; 70:e30128.\n\nXia, B; Liu, Y; Wang, J; Lu, Q; Lv, X; Deng, K; Yang, J. Emerging role of exosome-shuttled noncoding RNAs in gastrointestinal cancers: From intercellular crosstalk to clinical utility. Pharmacological Research. 2023; 195:106880.\n\nXie, Z; Starczynowski, DT. Are DDX41 variants of unknown significance and pathogenic variants created equal?. Haematologica: the hematology journal. 2023; 108:2883-2885.\n\nYamaguchi, A; van Hoorebeke, C; Tourdot, BE; Perry, S; Lee, G; Rhoads, N; Rickenberg, A; Green, A; Sorrentino, J; Yeung, J; Freedman, JC; Holman, TR; Holinstat, M. Fatty acids negatively regulate platelet function through formation of noncanonical 15-lipoxygenase-derived eicosanoids. Pharmacology Research and Perspectives. 2023; 11:e01056.\n\nYenwongfai, LN; Arora, R; Smith, AP; Kalfa, T; Husami, A; Radulescu, V; Myers, K; Lorsbach, R. Pediatric myelofibrosis due to compound heterozygous MPIG6B mutations in a patient of European ancestry. Pediatric Blood and Cancer. 2023; 70:e30023.\n\nYeom, SE; Cohen, B; Weiss, CR; Montano, C; Wohler, E; Sobreira, N; Hammill, AM; Comi, A. Genetic testing in the evaluation of individuals with clinical diagnosis of atypical Sturge-Weber syndrome. American Journal of Medical Genetics, Part A. 2023; 191:983-994.\n\nYoshimatsu, S; Okahara, J; Yoshie, J; Igarashi, Y; Nakajima, R; Sanosaka, T; Qian, E; Sato, T; Kobayashi, H; Morimoto, S; Kishi, N; Pillis, DM; Malik, P; Noce, T; Okano, H. Generation of a tyrosine hydroxylase-2A-Cre knockin non-human primate model by homology-directed-repair-biased CRISPR genome editing. Cell Reports: Methods. 2023; 3:100590.\n\nZhang, C; Cui, X; Liu, Y; Wang, F; Signer, R; Nattamai, K; Zhou, D; Zheng, Y; Geiger, H; Wan, F; Liang, Y. Latexin deletion protects against radiation-induced hematopoietic damages via selective activation of Bcl-2 prosurvival pathway. Haematologica: the hematology journal. 2023; 108:3464-3470.\n\nZhang, G; Odegard, E; Sabulski, DA; Jodele, S; Ziady, A; Seif, AE; Davies, SM; Laskin, B; Blackard, JT. 441 Evolution of BK Polyomavirus in Immunocompromised Pediatric Patients. Transplantation and cellular therapy. 2023; 29:s333-s334.\n\nZhang, J; Guan, M; Zhou, X; Berry, K; He, X; Lu, QR. Long Noncoding RNAs in CNS Myelination and Disease. The Neuroscientist: reviews at the interface of basic and clinical neurosciences. 2023; 29:287-301.\n\nZhang, Z; Wang, X; Lin, Y; Pan, D. A multifaceted evaluation of microgliosis and differential cellular dysregulations of mTOR signaling with fluctuating lysosome function in neuronopathic Gaucher disease. Molecular Genetics and Metabolism. 2023; 138:107366.\n\nZhou, ZH; Cortese, MM; Fang, JL; Wood, R; Hummell, DS; Risma, KA; Norton, AE; KuKuruga, M; Kirshner, S; Rabin, RL; Forshee, R; Broder, KR; Anderson, S; Kozlowski, S. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023; 41:4183-4189."
    }
}